Magnusson advised Quanterix Corporation

Magnusson advised Quanterix Corporation on its acquisition of Sweden-based UmanDiagnostics AB, world’s leading neurofilament light antibody supplier.

Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. Quanterix’ technology, Simoa, is designed to enable earlier disease detection, better prognoses and enhanced treatment methods. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.

The Magnusson core team comprised Anders Bäckman (Corporate/M&A), Helena Rönqvist (IP/IT), Karolin Eklund (Employment) and Caroline Landerfors (Insurance and Regulatory).